Comparing metabolomic and pathologic biomarkers alone and in combination for discriminating Alzheimer's disease from normal cognitive aging

Acta Neuropathologica Communications

Volumn 2, Issue 1, 2014, Pages

  Motsinger Reif, Alison A ^a   Zhu, Hongjie ^b   Kling, Mitchel A ^c,d   Matson, Wayne ^d   Sharma, Swati ^d   Fiehn, Oliver ^e   Reif, David M ^a   Appleby, Dina H ^c   Doraiswamy, P Murali ^b,f   Trojanowski, John Q ^c   Kaddurah Daouk, Rima ^b,f,g   Arnold, Steven E ^c  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b DUKE UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Cerebrospinal fluid biomarkers; Dementias; Metabolomics; Stepwise logistic regression

Indexed keywords

EID: 85005916228     PISSN: None     EISSN: 20515960     Source Type: Journal    
DOI: 10.1186/2051-5960-1-28     Document Type: Article

References (51)

1. Beach TG, Monsell SE, Phillips LE, Kukull W: Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 2012,71(4):266-273. 10.1097/NEN.0b013e31824b211b
2. Holtzman DM, Mandelkow E, Selkoe DJ: Alzheimer disease in 2020. Cold Spring Harb Perspect Med 2012,2(11):a011585. 10.1101/cshperspect.a011585
3. Morris JC, Selkoe DJ: Recommendations for the incorporation of biomarkers into Alzheimer clinical trials: an overview. Neurobiol Aging 2011,32(Suppl 1):S1-S3.
4. Selkoe DJ: Preventing Alzheimer's disease. Science 2012,337(6101):1488-1492. 10.1126/science.1228541
5. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ, Initiative A's D N: Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol [Internet] 2009,65(4):403-413. Accessed 30 Aug 2011 10.1002/ana.21610
6. Sperling RA, Johnson KA: Dementia: new criteria but no new treatments. Lancet Neurol 2011,11(1):4-5.
7. Trojanowski JQ, Arnold SE, Karlawish JH, Naylor M, Brunden KR, Lee VM: A model for improving the treatment and care of Alzheimer's disease patients through interdisciplinary research. Alzheimers Dement 2012,8(6):564-573. 10.1016/j.jalz.2011.08.005
8. Weiner MW, Aisen PS, Jack CR Jr, Jagust WJ, Trojanowski JQ, Shaw L, Saykin AJ, Morris JC, Cairns N, Beckett LA, Toga A, Green R, Walter S, Soares H, Snyder P, Siemers E, Potter W, Cole PE, Schmidt M, Initiative A's D N: Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimer's Dement 2010, 6: 202-211. 10.1016/j.jalz.2010.03.007
9. Yaffe K, Weston A, Graff-Radford NR, Satterfield S, Simonsick EM, Younkin SG, Younkin LH, Kuller L, Ayonayon HN, Ding J, Harris TB: Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA 2011,305(3):261-366. 10.1001/jama.2010.1995
10. Doraiswamy PM: Ask the Experts: What is the utility of amyloid imaging from the point of view of the clinician? Neurodegener Did Manag 2011,1(2):101-103. 10.2217/nmt.11.17
11. Yang L, Rieves D, Ganley C: Brain amyloid imaging-FDA approval of florbetapir F18 injection. N Engl J Med 2012,367(10):885-887. 10.1056/NEJMp1208061
12. Corona G, Rizzolio F, Giordano A, Toffoli G: Pharmaco-metabolomics: an emerging ''omics'' tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets. J Cell Physiol 2012, 227: 2827-2831. 10.1002/jcp.24003
13. Holmes E, Loo RL, Stamler J, Bictash M, Yap IK, Chan Q, Ebbels T, De Iorio M, Brown IJ, Veselkov KA, Daviglus ML, Kesteloot H, Ueshima H, Zhao L, Nicholson JK, Elliott P: Human metabolic phenotype diversity and its association with diet and blood pressure. Nature 2008,453(7193):396-400. 10.1038/nature06882
14. Johnson CH, Gonzalez FJ: Challenges and opportunities of metabolomics. J Cell Physiol 2012, 227: 2975-2981. 10.1002/jcp.24002
15. Kaddurah-Daouk R, Krishnan KR: Metabolomics: A global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology 2009,34(1):173-186. 10.1038/npp.2008.174
16. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM: Metabolomics: A global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 2008, 48: 653-683. 10.1146/annurev.pharmtox.48.113006.094715
17. Kristal BS, Shurubor YI, Kaddurah-Daouk R, Matson WR: High-performance liquid chromatography separations coupled with coulometric electrode array detectors: a unique approach to metabolomics. Methods Mol Biol 2007, 358: 159-174. 10.1007/978-1-59745-244-1_10
18. Maddox JF, Luyendyk JP, Cosma GN, Breau AP, Bible RH Jr, Harrigan GG, Goodacre R, Ganey PE, Cantor GH, Cockerell GL, Roth RA: Metabonomic evaluation of idiosyncrasy-like liver injury in rats cotreated with ranitidine and lipopolysaccharide. Toxicol Appl Pharmacol 2006,212(1):35-44. 10.1016/j.taap.2005.06.021
19. Mamas M, Dunn WB, Neyses L, Goodacre R: The role of metabolites and metabolomics in clinically applicable biomarkers of disease. Arch Toxicol 2011, 85: 5-17. 10.1007/s00204-010-0609-6
20. Mendes P: Metabolomics and the challenges ahead. Brief Bioinform 2006, 7: 127. 10.1093/bib/bbl010
21. Patti GJ, Yanes O, Siuzdak G: Innovation: Metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 2012, 13: 263-269. 10.1038/nrm3314
22. van der Greef J, Hankemeier T, McBurney RN: Metabolomics-based systems biology and personalizedmedicine: moving towards n=1 clinical trials? Pharmacogenomics 2006, 7: 1087-1094.10.2217/14622416.7.7.1087
23. Viswanathan A, Rocca WA, Tzourio C: Vascular risk factors and dementia: how to move forward? Neurology 2009, 72: 368-374. 10.1212/01.wnl.0000341271.90478.8e
24. Kaddurah-Daouk R, Rozen S, Matson W, Han X, Hulette CM, Burke JR, Doraiswamy PM, Welsh-Bohmer KA: Metabolomic changes in autopsy-confirmed Alzheimer's disease. Alzheimers Dement 2011,7(3):309-317. 10.1016/j.jalz.2010.06.001
25. Han X, Rozen S, Boyle SH, Hellegers C, Cheng H, Burke JR, Welsh-Bohmer KA, Doraiswamy PM, Kaddurah-Daouk R: Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One 2011,6(7):e21643. 10.1371/journal.pone.0021643
26. Condray R, Dougherty GG, Keshavan MS, Reddy RD, Haas GL, Montrose DM, Matson WR, McEvoy J, Kaddurah-Daouk R, Yao JK: 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. Int J Neuropsychopharmacol 2011, 28: 1-12.
27. Kaddurah-Daouk R, McEvoy J, Baillie RA, Lee D, Yao JK, Doraiswamy PM, Krishnan KR: Metabolomic mapping of atypical antipsychotic effects in schizophrenia. Mol Psychiatry 2007,12(10):934-945. 10.1038/sj.mp.4002000
28. Yao JK, Condray R, Dougherty GG Jr, Keshavan MS, Montrose DM, Matson WR, McEvoy J, Kaddurah-Daouk R, Reddy RD: Associations between purine metabolites and clinical symptoms in schizophrenia. PLoS One 2012,7(8):e42165. Epub 2012 Aug 14 10.1371/journal.pone.0042165
29. Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, McEvoy J, Kaddurah-Daouk R: Homeostatic imbalance of purine catabolism in first-episode neuroleptic-naïve patients with schizophrenia. PLoS One 2010,5(3):e9508. 10.1371/journal.pone.0009508
30. Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR, Rozen S, Krishnan RR, McEvoy J, Kaddurah-Daouk R: Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry 2009, 28: 1-16.
31. Kaddurah-Daouk R, Yuan P, Boyle SH, Matson W, Wang Z, Zeng ZB, Zhu H, Dougherty GG, Yao JK, Chen G, Guitart X, Carlson PJ, Neumeister A, Zarate C, Krishnan RR, Manji HK, Drevets W: Cerebrospinal fluid metabolome in mood disorders-remission state has a unique metabolic profile. Sci Rep 2012, 2: 667. Epub 2012 Sep 19
32. Paige LA, Mitchell MW, Krishnan KR, Kaddurah-Daouk R, Steffens DC: A preliminary metabolomic analysis of older adults with and without depression. Int J Geriatr Psychiatry 2007,22(5):418-423. 10.1002/gps.1690
33. Steffens DC, Jiang W, Krishnan KR, Karoly ED, Mitchell MW, O'Connor CM, Kaddurah-Daouk R: Metabolomic differences in heart failure patients with and without major depression. J Geriatr Psychiatry Neurol 2010,23(2):138-146. 10.1177/0891988709358592
34. Kaddurah-Daouk R, Boyle SH, Matson W, Sharma S, Matson S, Zhu H, Bogdanov MB, Churchill E, Krishnan RR, Rush AJ, Pickering E, Delnomdedieu M: Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept. Transl Psychiatry 2011, 1: e26. 10.1038/tp.2011.22
35. Kaddurah-Daouk R, Zhu H, Rozen S, Matson W, Sharma S, Oki NO, Motsinger-Reif AA, Bogdanov M, Churchill E, Lei Z, Kling MA, Trojanowski JQ, Arnold SE, Doraiswamy PM: Alterations in metabolic pathways and networks in mild cognitive impairment and early Alzheimer's disease. Transl Psychiatry 2013, 3: e244. 10.1038/tp.2013.18
36. Kaddurah-Daouk R, Baillie RA, Zhu H, Zeng ZB, Wiest MM, Nguyen UT, Watkins SM, Krauss RM: Lipidomic analysis of variation in response to simvastatin in the cholesterol and pharmacogenetics study. Metabolomics 2010, 6: 191-2011. 10.1007/s11306-010-0207-x
37. Mannelli P, Patkar A, Rozen S, Matson WR, Krishnan R, Kaddurah-Daouk R: Opioid use affects antioxidant activity and purine metabolism: Preliminary results. Hum Psychopharmacol 2009,24(8):666-675. 10.1002/hup.1068
38. Patkar AA, Rozen S, Mannelli P, Matson W, Pae CU, Krishnan RR, Kaddurah-Daouk R: Alterations in tryptophan and purine metabolism in cocaine addiction: A metabolomic study. Psychopharmacology (Berl) 2009,206(3):479-489. 10.1007/s00213-009-1625-1
39. Geisser S: Predictive Inference. New York, NY: Chapman and Hall; 1993.
40. Clark CM, Ewbank DC: Performance of the dementia severity rating scale: a caregiver questionnaire for rating severity in Alzheimer disease. Alzheimer Dis Assoc Disord 1996,10(1):31-39.
41. Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS, Flint Beal M: Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 2008,131(Pt 2):389-396.
42. Johansen KK, Wang L, Aasly JO, White LR, Matson WR, Henchcliffe C, Beal MF, Bogdanov M: Metabolomic profiling in LRRK2-related Parkinson's disease. PLoS One 2009,4(10):e7551. 10.1371/journal.pone.0007551
43. Rozen S, Cudkowicz ME, Bogdanov M, Matson WR, Kristal BS, Beecher C, Harrison S, Vouros P, Flarakos J, Vigneau-Callahan K, Matson TD, Newhall KM, Beal MF, Brown RH Jr, Kaddurah-Daouk R: Metabolomic analysis and signatures in motor neuron disease. Metabolomics 2005,1(2):101-108. 10.1007/s11306-005-4810-1
44. Kind T, Wohlgemuth G, Lee DY, Lu L, Palazoglu M, Shahbaz S, Fiehn O: FiehnLib: mass spectral and retention index libraries for metabolomics based on quadrupole and time-of-flight gas chromatography/mass spectrometry. Anal Chem 2009, 81: 10038-10048. 10.1021/ac9019522
45. Folstein MF, Folstein S, McHugh PR: Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12: 189-198. 10.1016/0022-3956(75)90026-6
46. Devijver PA, Kittler J: Pattern Recognition: A Statistical Approach. London, GB: Prentice-Hall; 1982.
47. Kohavi R Proceedings of the Fourteenth International Joint Conference on Artificial Intelligence. In A study of cross-validation and bootstrap for accuracy estimation and model selection. San Mateo, CA: Morgan Kaufmann; 1995:1137-1143. 2 (12)
48. Chyan YJ, Poeggeler B, Omar RA, Chain DG, Frangione B, Ghiso J, Pappolla MA: Potent neuroprotective properties against the Alzheimer β-Amyloid by an endogenous melatonin-related indole structure, Indole-3-propionic acid. J Biol Chem 1999, 274: 21937-21942. 10.1074/jbc.274.31.21937
49. Hwang IK, Yoo KY, Li H, Park OK, Lee CH, Choi JH, Jeong YG, Lee YL, Kim YM, Kwon YG, Won MH: Indole-3-propionic acid attenuates neuronal damage and oxidative stress in the ischemic hippocampus. J Neurosci Res 2009,87(9):2126-2137. 10.1002/jnr.22030
50. Baran H, Jellinger K, Deecke L: Kynurenine metabolism in Alzheimer's disease. J Neural Transm 1999,106(2):165-181. 10.1007/s007020050149
51. Gulaj E, Pawlak K, Bien B, Pawlak D: Kynurenine and its metabolites in Alzheimer's disease patients. Adv Med Sci 2010,55(2):204-211. 10.2478/v10039-010-0023-6